NEW YORK (GenomeWeb) – Israeli cancer diagnostics developer NovellusDx has raised $10 million in a private financing round.

The round, led by life sciences holding company IntraCure and life sciences venture capital financier Pontifax, includes an option for an additional $10 million investment, the company said in a statement.

Founded in 2012, the firm has developed technology to monitor signaling pathways and identify driver mutations in different kinds of cancer, and monitor the effects of targeted therapies on those mutations.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.